ACRV - Acrivon Therapeutics Inc Common Stock Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Market Current Price & Safety Score Price: 1.72 USD StockBonds Safety Grade: F Altman Z-Score (Bankruptcy Risk): -2.54 StockBond Score: -2.69 Company Description Acrivon Therapeutics Inc operates as a clinicalstage biopharmaceutical company primarily focused on creating oncology treatments The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications utilizing its proprietary proteomicsbased platform for patient identification This advanced system named Acrivon Predictive Precision Proteomics AP3 serves as a precision medicine tool It is instrumental in developing drugspecific OncoSignature companion diagnostics which are designed to pinpoint individuals most likely to benefit from the companys therapeutic candidates Acrivons flagship clinical asset is ACR368 a selective small molecule inhibitor that targets both CHK1 and CHK2 This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types notably including platinumresistant ovarian endometrial and bladder cancers Beyond its lead program the company is also cultivating several earlystage pipeline programs These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways specifically identifying targets such as the protein kinases WEE1 and PKMYT1 Established in 2018 Acrivon Therapeutics Inc maintains its headquarters in Watertown Massachusetts